• Cytokinetics Inc., of South San Francisco, reported results from two Phase II studies of CK-2017357 in amyotrophic lateral sclerosis (ALS), showing that the drug was safe and well tolerated when dosed with Rilutek (riluzole, Sanofi SA), the only approved treatment for ALS. Data were presented at the Academy of Neurology meeting in New Orleans.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter